PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Prostatic Neoplasms”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 721 records · Page 40Linked to original sources
PubMed2000

Prostate volume change after radioactive seed implantation: possible benefit of improved dose volume histogram with perioperative steroid.

PURPOSE: To evaluate the changes in prostate volume associated with radioactive seed implantation and identify factors that influence prostate swelling. METHODS AND MATERIALS: Between June 1997 and August 1999, 161 patients implanted for prostate carcinoma at the University of California, San Francisco, had prostate volume measurements taken at 4 time points (preplan, preimplant, postimplant, postimplant dosimetry). Patient records were reviewed for treatment with perioperative steroids, hormone therapy (nHT), and external beam radiotherapy (EBRT). One and 2-way analysis of variance (ANOVA) methods were used to test differences in mean effects among patient subsets. RESULTS: A mean 20% volume increase was noted immediately postimplant overall (p < 0.0001), and even with EBRT and/or HT. Steroids were associated with a mean volume decrease of 19.9%, by 3-4 weeks post-procedure (p < 0.0001). Without steroids, only a 3.8% mean change was seen (p = ns). Steroid use resulted in a significant increase in mean dose-volume histogram (DVH) (p = 0.001); however, this benefit was only observed among patients who did not receive steroid. A consistently high DVH occurred with steroid use. CONCLUSION: A significant decrease in prostate volume and improved DVH are associated with steroid use. The diminished benefit of steroid use and higher mean DVH achieved in later years suggests the existence of a significant "learning curve" for brachytherapy procedures.

Aged↗
PubMed2003

Facilitation of radiotherapeutic error by computerized record and verify systems.

PURPOSE: To examine the impact of computerized record and verify (R&V) systems on types of radiotherapeutic error. MATERIALS AND METHODS: Radiation therapy treatment errors reported by therapists at the University of Utah between July 1, 1999 and June 30, 2000 were retrospectively reviewed. RESULTS: During a 1-year period in which 22,542 external beam radiation therapy treatments were administered, 38 treatment errors (representing 0.17% of external beam treatments administered during this period) were identified and reviewed. Nine cases (0.04% of treatments) representing four types of record and verify (R&V)-related errors were identified, in which the department's R&V system played a contributory role in the treatment error. CONCLUSIONS: The common denominator among these R&V-related errors was excessive reliance upon the computer system by therapists. R&V systems eliminate some, but not all, pathways of radiotherapeutic error. Although R&V systems have assumed a crucial role in the precise and reproducible delivery of increasingly complex radiation therapy treatments, their inability to eradicate all radiotherapeutic errors coupled with their parallel ability to facilitate certain mistakes mandates vigilance on the part of the radiation therapy team. Radiation therapy treatment procedures must preserve careful oversight of R&V functions to minimize prospects for treatment error.

Adenocarcinoma↗
PubMed1999

Prostate brachytherapy in patients with prior evidence of prostatitis.

PURPOSE: To refute a misconception that a prior history of prostatitis is a contraindication to prostate brachytherapy. METHODS AND MATERIALS: Five patients with clinical or pathologic evidence of prior prostatitis were treated with transperineal brachytherapy. Four of the patients received a single i.v. dose of ciprofloxacin (500 mg) intraoperatively. Postimplant antibiotics were not given. The pretreatment biopsy slides were reviewed. RESULTS: Two of the five patients developed postimplant urinary retention requiring short-term catheterization, and both resolved spontaneously. One patient developed what appeared to be an exacerbation of his chronic prostatitis. CONCLUSION: We continue to recommend prostate brachytherapy for the treatment of clinically organ-confined cancer, with no concern about prior clinical or pathologic evidence of prostatitis.

Aged↗
PubMedDate not supplied

The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate.

The aim was to evaluate the role of dynamic magnetic resonance (MR) imaging for prostatic carcinoma. Forty-two men with clinical suspicion of a prostatic carcinoma underwent MR imaging. Dynamic MR was performed, followed by postcontrast T1-weighted imaging with fat suppression. Histologic diagnosis was 21 prostatic carcinomas (in 19 patients), 21 benign tissues, and 2 chronic prostatitis. The diagnostic accuracy was 75% for T2-weighted images, and 79% for dynamic images. The accuracy of the combination of dynamic MR images with postcontrast T1-weighted images was 82%. It was concluded that dynamic MR imaging was useful in differentiation of low intensity lesions in the peripheral zone.

Aged↗
PubMed2001

Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3.

The ERBB3 gene is expressed as a 6.2- and a 1.4-kb transcript. The former encodes the full-length transmembrane protein and the latter a truncated extracellular fragment consisting of 140 amino acids of the c-erbB-3 protein followed by 43 unique residues. We have examined the expression of the two ERBB3 transcripts by Northern blotting in cancer cell lines and normal human fetal and adult tissues. We expressed the truncated receptor fragment and showed that it was glycosylated, probably with a single N-linked complex sugar chain, and that the protein was a 58-kDa disulphide-linked dimer. We were able to crosslink iodinated neuregulin (NRG)-1beta to the full-length solubilised receptor but not to the truncated dimeric protein. Using Western blot analysis, the truncated protein was shown to be present in cell lysates and, using immunoelectron microscopy, in vesicular structures within cells and associated with the plasma cell membrane.

Animals↗
PubMed2001

Radiotherapy.

Explore the source record for details and available documents.

Aged↗
PubMed1998

Antitumour activity and schedule dependency of 8-chloroadenosine-3',5'-monophosphate (8-ClcAMP) against human tumour xenografts.

8-Chloroadenosine-3',5'-monophosphate (8-ClcAMP) is a novel antitumour agent currently undergoing phase I clinical trials in several European centres. In this study, its antitumour activity against human tumour xenografts and its dependence on schedule were investigated. When administered by continuous infusion at doses of 100 or 50 mg/kg/day to nude mice bearing human tumour xenografts, 8-ClcAMP inhibited the growth of the HT 29 colorectal, ZR-75-1 breast, HOX 60 and PE04 ovarian and PANC-1 pancreatic carcinoma xenografts. However, these infusion schedules produced hypercalcaemia and severe weight loss. In an attempt to optimise antitumour activity and minimise toxicity, several other schedules were studied. In comparison with continuous administration of 8-ClcAMP at 50 mg/kg/day for 14 days which, although producing complete growth inhibition in the HOX 60 model, was associated with a marked body weight loss, schedules in which the infusion was interrupted (infusion on either days 0-4; 7-11 or days 0-2; 6-8) produced minimal weight loss but also reduced antitumour activity. However, co-administration of salmon calcitonin with continuous infusion of 8-ClcAMP prevented both hypercalcaemia and body weight loss in 3/6 animals while still producing marked inhibition of tumour growth. These data indicate that 8-ClcAMP has broad-spectrum antitumour activity and the major side-effect of hypercalcaemia may at least in part be ameliorated by the use of salmon calcitonin.

8-Bromo Cyclic Adenosine Monophosphate↗
PubMed1999

Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED-110.

All four "symmetrical" regioisomers of ED-110, an indolocarbazole derivative having potent activity against human topoisomerase I (Topo I) were synthesized. The isomer containing hydroxyl groups in the 3- and 9-positions was approximately ten-fold more active against Topo I, and 5- to 35-fold more active against human solid tumor cell lines in vitro, relative to ED-110.

Antineoplastic Agents↗
PubMed2000

Segmentation and counting of FISH signals in confocal microscopy images.

In this paper we have presented a semi-automatic method for segmenting and counting the Fluorescence In Situ Hybridization (FISH) signals per cell nucleus in a 3D tissue image. The number of FISH signals indicate the gain (trisomy) or loss (monosomy) of certain base-sequences in deoxyribonucleic acid (DNA). The quantitative evaluation of the loss or gain in DNA is necessary in qualitative diagnostic molecular pathology. Multispectral volumetric images are obtained using the Confocal Microscope. Each consists of a red channel depicting the 3D morphology of the tissue and green channel containing the FISH signals. The red channel tissue image is segmented first to determine the membership of the FISH signal to a particular nuclei. Various segmentation methods starting from simple local thresholding to volume growing and active volumes are used for segmentation. A brief comparative study of the visual signal count by pathologist and our automatic count is also presented.

Cell Nucleus↗
PubMed2003

Short course radiation therapy for elderly cancer patients. Evidences from the literature review.

The choice of the appropriate treatment strategy for elderly cancer patients may be a difficult challenge. Radiation therapy is commonly offered to these patients, but treatment duration may represent a limiting factor, as many patients cannot tolerate a conventional course of radiotherapy (RT) due to age-related medical or logistic problems. Hypofractionated RT may represent a very convenient choice, but it entails an increased risk of late toxicity occurrence. We made a literature review to define the possible role of hypofractionated RT for elderly cancer patients. As expected, we found out that short irradiation schedules are more commonly employed for treatments with palliative aims but a more widespread use of these regimes is still controversial. The lack of prospective trials tailored for these patients makes even more difficult to tailor the choice of treatment on standardised treatment guidelines. Nevertheless our review highlights that for several tumour types RT can be scheduled conveniently and effectively in order to achieve local disease control and/or symptom relief with the least discomfort and treatment-related morbidity for elderly patients.

Aged↗
PubMed2001

The use of dendritic cells in cancer therapy.

Although the immune system evolved to protect the host from infection, what fires the popular imagination is its potential to recognise and destroy cancer. The immune system can generate potent cytotoxicity (eg transplant rejection), but can these mechanisms be harnessed for therapeutic benefit in patients with cancer? The discovery of an ever-increasing array of tumour antigens shows clearly that the targets exist. The challenge lies in generating a sufficiently potent response towards them. Central to the processes of antigen recognition, processing, and presentation to the immune system are dendritic cells. Understanding of the relation between these and the cellular immune response is crucial to elucidation of how to manipulate immune responses. The past 20 years have witnessed a dramatic expansion in this understanding and led to the first early-phase clinical trials of dendritic cells for the treatment of cancer. These studies have established the safety and feasibility of this approach and have produced encouraging evidence of therapeutic efficacy. This paper reviews the biology of dendritic cells and their use in clinical trials, as well as highlighting issues for future trial design.

Adjuvants, Immunologic↗